Sensor-augmented pump therapy in very young children with type 1 diabetes: An efficacy and feasibility observational study

Giulio Frontino, Riccardo Bonfanti, Andrea Scaramuzza, Ivana Rabbone, Franco Meschi, Andrea Rigamonti, Roseila Battaglino, Valeria Favalli, Clara Bonura, Sabrina Sicignano, Elisa Gioia, Gian Vincenzo Zuccotti, Franco Cerutti, Giuseppe Chiumello

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Efficacy and feasibility of sensor-augmented pump (SAP) therapy were evaluated in very young children with type 1 diabetes (T1D). Subjects and Methods: SAP (Dexcom [San Diego, CA] Seven Plus™ usage combined with insulin pump) therapy was retrospectively evaluated in 28 children (15 boys) younger than 7 years (mean age, 5.8±1.2 years; range, 3-7 years), with T1D. Glycosylated hemoglobin (HbA1c) was evaluated at baseline and at the end of the study, as were efficacy and feasibility of the system, using a rating scale (with 3 being the most positive). Results: SAP has been used for at least 6 months by 85% of patients, with an overall good satisfaction (92%). The greatest perceived benefit was the reduced fear of hypoglycemia (score of 3, 81%). HbA1c significantly improved only in patients with baseline HbA1c >7.5% (P=0.026). Conclusions: SAP therapy is effective and feasible in preschool children with T1D. In patients with high HbA1c at baseline it provide a 0.9% decrease, sustained for at least 6 months.

Original languageEnglish
Pages (from-to)762-764
Number of pages3
JournalDiabetes Technology and Therapeutics
Volume14
Issue number9
DOIs
Publication statusPublished - Sep 1 2012

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Sensor-augmented pump therapy in very young children with type 1 diabetes: An efficacy and feasibility observational study'. Together they form a unique fingerprint.

Cite this